Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Nasdaq Real Time Price USD

Longeveron Inc. (LGVN)

Compare
1.5800
-0.1200
(-7.06%)
At close: March 28 at 4:00:00 PM EDT
1.5800
0.00
(0.00%)
Pre-Market: 4:14:49 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,392
2,392
709
1,222
1,306
Cost of Revenue
508
508
488
725
716
Gross Profit
1,884
1,884
221
497
590
Operating Expense
18,406
18,406
21,250
18,540
18,046
Operating Income
-16,522
-16,522
-21,029
-18,043
-17,456
Net Non Operating Interest Income Expense
--
--
--
--
-4
Other Income Expense
549
549
-384
-792
415
Pretax Income
-15,973
-15,973
-21,413
-18,835
-17,045
Net Income Common Stockholders
-24,623
-24,623
-22,211
-18,835
-17,045
Diluted NI Available to Com Stockholders
-24,623
-24,623
-22,211
-18,835
-17,045
Basic EPS
-2.62
--
-1.02
-9.00
-9.00
Diluted EPS
-2.62
--
-1.02
-9.00
-9.00
Basic Average Shares
9,411.1640
--
21,734.9000
2,096.9030
1,891.5080
Diluted Average Shares
9,411.1640
--
21,734.9000
2,096.9030
1,891.5080
Total Operating Income as Reported
-16,522
-16,522
-21,029
-18,043
-17,456
Total Expenses
18,914
18,914
21,738
19,265
18,762
Net Income from Continuing & Discontinued Operation
-15,973
-15,973
-21,413
-18,835
-17,045
Normalized Income
-15,973
-15,973
-21,383
-17,437
-17,345
Interest Expense
--
--
--
--
4
Net Interest Income
--
--
--
--
-4
EBIT
-16,522
-16,522
-21,029
-18,043
-17,041
EBITDA
-15,564
-15,564
-20,083
-17,150
-16,127
Reconciled Cost of Revenue
508
508
488
725
716
Reconciled Depreciation
958
958
946
893
914
Net Income from Continuing Operation Net Minority Interest
-15,973
-15,973
-21,413
-18,835
-17,045
Total Unusual Items Excluding Goodwill
--
--
-30
-1,398
300
Total Unusual Items
--
--
-30
-1,398
300
Normalized EBITDA
-15,564
-15,564
-20,053
-15,752
-16,427
12/31/2021 - 2/12/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KTTA Pasithea Therapeutics Corp.
1.3400
+1.52%
 
ENSC Ensysce Biosciences, Inc.
3.2500
+3.17%
 
ZVSA ZyVersa Therapeutics, Inc.
0.6082
-10.76%
 
VRAX Virax Biolabs Group Limited
1.1600
-7.20%
 
SPRC SciSparc Ltd.
0.3080
-4.05%
 
CERO CERo Therapeutics Holdings, Inc.
0.7510
-1.83%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.2418
-14.68%
 
CMND Clearmind Medicine Inc.
1.0700
+1.90%
 
VRPX Virpax Pharmaceuticals, Inc.
1.3400
-9.46%
 
UBX Unity Biotechnology, Inc.
1.1400
-3.39%